Veracyte Q2 Revenue Beats, Raises 2026 Guidance on Strong Test Sales
VCYT has more than doubled off its 52-week low of $22.92.
Summary
Veracyte delivered a strong Q2, with revenue of $150.3M beating consensus by about 4% and rising 15% year-over-year. Growth was driven by Decipher and Afirma test sales, up 20% and 18% respectively. The company also launched two new cancer tests during the quarter. Management raised full-year 2026 revenue guidance to $590M-$596M, above the prior $582M-$592M range, and expects adjusted EBITDA margin above 26%. This follows a robust Q1 and recent Medicare coverage for the TrueMRD test, reinforcing the commercial momentum. The stock is likely to react positively to the beat and raised outlook.
Updates
· SEC 10-Q — Net income was $25.5 million, or $0.32 per share, compared with a net loss of $1.0 million a year earlier. Six-month net income was $54.2 million.
At the time of this announcement, VCYT was trading at $52.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $22.92 to $60.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.